PLYMOUTH, Mich. – March 27, 2011 – Lycera Corporation, a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that the company presented at the following industry conferences:
- Society for Biomolecular Sciences (SBS) 17th Annual Conference and Exhibition, held March 27-31 in Orlando, Fla. Xiao Hu, Ph.D., senior director, biology gave a presentation titled “Identification and Characterization of Potent and Selective Antagonists of the Nuclear Receptor RORc,” during the “Case Studies for Hot Targets: From the Lab to Lead Compounds” session.
In the presentation, Dr. Hu reported the identification and characterization of novel, potent and selective antagonists of RORγ that represent high quality candidates for further pre-clinical drug development.
- Evolving Approaches to Early-Stage Drug Discovery, part of the Keystone Symposia on Molecular and Cellular Biology, held April 3-7 in Snowbird, Utah. Peter L. Toogood, Ph.D., senior vice president, chemistry and chemical biology, gave a presentation titled “Autoimmune Disease Modification through Mitochondrial Bioenergetics.”
In his presentation, Dr. Toogood discussed how modulation of the mitochondrial ATPase can provide a selective, non-immunosuppressive mechanism for the treatment of inflammation and autoimmune disease. In addition, he described the discovery of a novel series of compounds that modulate the ATPase and exhibit therapeutic efficacy in murine disease models.
Lycera Corp. is focused on the discovery and development of selective, small-molecule immunomodulators for the treatment of patients with autoimmune diseases such as rheumatoid arthritis, psoriasis and inflammatory bowel disease. Lycera is developing drug candidates that target two novel therapeutic pathways and have the potential for first-in-class oral efficacy without the adverse effects of current standard-of-care antiproliferative and immunosuppressive agents. Lycera is focused on the emerging area of cellular bioenergetics to selectively target and silence pathologically activated cells. The company also has a program targeting the Th17 pathway through the inhibition of RORγt. Lycera’s leadership team and advisors represent the core thought leaders in immunology, inflammation, organ transplantation and kinase biology and are responsible for key advances and discoveries in these fields. Visit www.lycera.com for more information.